Skip to content
value.today

VenatoRx Pharmaceuticals, Inc.

🇺🇸 Malvern, Pennsylvania, USABiotechnologyFounded 2010
Total raised
$124 M
5 rounds on record
Latest round
$35 M
Feb 2023
First round on record
Nov 2013
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of VenatoRx Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2023$35 MNo. 5$10 to $50 million

VenatoRx Pharmaceuticals, Inc.: Raise no. 5, Feb 2023

Investors in this round

3 investors had bought by the notice of Jul 13, 2023: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $48 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,550,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony J Meehan · Executive Officer
  • Christopher J Burns · Executive Officer, Director
  • Daniel C Pevear · Executive Officer
  • Martin J Heidecker · Director
  • Sergei J Petukhov · Director
  • Timothy J Haines · Director
  • Tomas C Heyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher J. Burns, President. Source: SEC Form D and 1 amendment, newest notice filed Jul 13, 2023. Read the notice at the SEC.

debt, optionsSEC
Aug 2022$25 MNo. 4$10 to $50 million

VenatoRx Pharmaceuticals, Inc.: Raise no. 4, Aug 2022

Investors in this round

2 investors had bought by the notice of Dec 22, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,000,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony J. Meehan · Executive Officer
  • Christopher J. Burns · Executive Officer, Director
  • Daniel C. Pevear · Executive Officer
  • Ezra J. Felker · Executive Officer
  • Timothy J. Henkel · Executive Officer
  • Martin J. Heidecker · Director
  • Michael C. Diem · Director
  • Sergei J. Petukhov · Director
  • Timothy J. Haines · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher J. Burns, President. Source: SEC Form D and 1 amendment, newest notice filed Dec 22, 2022. Read the notice at the SEC.

equitySEC
Mar 2022$34 MNo. 3$10 to $50 million

VenatoRx Pharmaceuticals, Inc.: Raise no. 3, Mar 2022

Investors in this round

3 investors had bought by the notice of Apr 4, 2022: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$34 M of $60 M offered; $26 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony J. Meehan · Executive Officer
  • Christopher J. Burns · Executive Officer, Director
  • Daniel C. Pevear · Executive Officer
  • Ezra J. Felker · Executive Officer
  • Timothy J. Henkel · Executive Officer
  • Martin J. Heidecker · Director
  • Michael J. Diem · Director
  • Sergei J. Petukhov · Director
  • Timothy J. Haines · Director
  • Vincent J. Milano · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher J. Burns, President. Source: SEC Form D, newest notice filed Apr 4, 2022. Read the notice at the SEC.

equitySEC
Jul 2017$27 MNo. 2$10 to $50 million

VenatoRx Pharmaceuticals, Inc.: Raise no. 2, Jul 2017

Investors in this round

47 investors had bought by the notice of Nov 5, 2018: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $47 M offered; $20 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Burns · Executive Officer, Director
  • Daniel C. Pevear · Executive Officer
  • Ezra J. Felker · Executive Officer
  • Carlo J. Rizzuto · Director
  • Michael J. Diem · Director
  • Shelley J. Chu · Director
  • Vincent J. Milano · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher J. Burns, President. Source: SEC Form D and 1 amendment, newest notice filed Nov 5, 2018. Read the notice at the SEC.

equity, optionsSEC
Nov 2013$3 MNo. 1$2 to $10 million

VenatoRx Pharmaceuticals, Inc.: Raise no. 1, Nov 2013

Investors in this round

59 investors had bought by the notice of Dec 4, 2013: 59 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
$15,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$175,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Burns · Executive Officer, Director
  • Daniel C. Pevear · Executive Officer, Director
  • Luigi J. Xerri · Executive Officer, Director
  • Vincent J. Milano · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes payments made pursuant to the conversion of outstanding indebtedness”

Signed by Christopher J. Burns, President. Source: SEC Form D, newest notice filed Dec 4, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • VenatoRx Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2023).

    SEC Form D · Jul 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2023

That is all the official record says: VenatoRx Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of VenatoRx Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 59 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by VenatoRx Pharmaceuticals, Inc.
NameRoleNamed in
Anthony J MeehanExecutive officerJul 2023
Christopher J BurnsExecutive officerJul 2023
Daniel C PevearExecutive officerJul 2023
Ezra J FelkerExecutive officerFeb 2023
Anthony J. MeehanExecutive officerDec 2022
Christopher J. BurnsExecutive officerDec 2022
Daniel C. PevearExecutive officerDec 2022
Ezra J. FelkerExecutive officerDec 2022
Timothy J. HenkelExecutive officerDec 2022
James J. MurphyExecutive officerJul 2017
Luigi J. XerriExecutive officerJul 2017
Tim J. HenkelExecutive officerJul 2017
Christopher J BurnsDirectorJul 2023
Martin J HeideckerDirectorJul 2023
Sergei J PetukhovDirectorJul 2023
Timothy J HainesDirectorJul 2023
Tomas C HeymanDirectorJul 2023
Michael C DiemDirectorFeb 2023
Christopher J. BurnsDirectorDec 2022
Martin J. HeideckerDirectorDec 2022
Michael C. DiemDirectorDec 2022
Sergei J. PetukhovDirectorDec 2022
Timothy J. HainesDirectorDec 2022
Michael J. DiemDirectorApr 2022
Vincent J. MilanoDirectorApr 2022
Carlo J. RizzutoDirectorNov 2018
Shelley J. ChuDirectorNov 2018
Daniel C. PevearDirectorDec 2013
Luigi J. XerriDirectorDec 2013